# US 2006/0079469 A1 · Anti-restenosis agent

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2006/0079469 A1
- Document ID: US20060079469A1
- Status: Published application
- Kind: A1
- Application number: 10/493,486
- Filed: 2002-10-25
- Published: 2006-04-13
- Earliest claimed: 2001-10-26
- Assignees: Cube Medical A/S; Centre National De La Recherche Scientifique
- Inventors: Erik Anderson; Trung Le Doan; Laurent Lamidey
- Web page: https://patentgrep.com/patent/US20060079469A1

## CPC

- A61L 31/16: Biologically active materials, e.g. therapeutic substances {(A61L31/047 takes precedence)}
- A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A61L: METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES (preservation of bodies or disinfecting characterised by the agents employed A01N; preserving, e.g. sterilising, food or foodstuffs A23; preparations for medical, dental or toiletry purposes A61K)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

An anti-restenosis agent comprises a phosphorothioate-modified oligonucleotide includes at least on hairpin loop and a TG sequence. The hairpin loop preferably has the sequence CAG CGA AGC. Especially preferred oligonucleotides are ones which include a sequence selected from TGGGG TGGGG T GGGGT GGGGT CAG CGA AGC (SEQ ED NO: 4) and TTGGG TTGGG T GGGTT GGGTT CAG CGA AGC (SEQ TD NO: 6). The anti-restenosis agent may be used as or in a coating on a device for implantation into the body, for instance a stent.

## Claims

### Claim 1

An anti-restenosis agent comprising a phosphorothioate-modified oligonucleotide, wherein the oligonucleotide includes at least one hairpin loop and a dT or dG releasing group (TG).

### Claim 2 (depends on 1)

An anti-restenosis agent as claimed in claim 1, in which the hairpin loop is located adjacent a 3′ or 5′ end of the oligonucleotide.

### Claim 3 (depends on 1, 2)

An anti-restenosis agent as claimed in either claim 1 or claim 2, wherein the hairpin loop comprises the sequence XYG CGA AGC, in which each of X and Y is independently selected from the four nucleotides dA, dT, dG and dC.

### Claim 4 (depends on 1)

An anti-restenosis agent as claimed in claim 1, in which the TG sequence adjoins the hairpin loop sequence.

### Claim 5 (depends on 4)

An anti-restenosis agent as claimed in claim 4, wherein the oligonucleotide has a terminal sequence CAGCGAAGCTG (SEQ ID NO: 8).

### Claim 6 (depends on 1)

An anti-restenosis agent as claimed in claim 1, in which the oligonucleotide comprises from 30 to 100 bases.

### Claim 7 (depends on 1)

An anti-restenosis agent as claimed in claim 1, in which the phosphorothioate modified oligonucleotide includes at least one multi-guanosine sequence.

### Claim 8 (depends on 7)

An anti-restenosis agent according to claim 7, wherein the multi-guanosine sequence is selected from TGGGG, TGGG and TTGGG.

### Claim 9 (depends on 1)

An anti-restenosis agent according to claim 1, wherein the oligonucleotide comprises a core portion having a central T immediately preceded by a first multi-guanosine sequence and followed immediately by a second multi-guanosine sequence which is a mirror image of the said first multi-guanosine sequence.

### Claim 10 (depends on 9)

An anti-restenosis agent according to claim 9, wherein the oligonucleotide includes the sequence TGG GGT GGG GTG GGG TGG GGT (SEQ ID NO: 2).

### Claim 11 (depends on 9)

An anti-restenosis agent according to claim 9, wherein the oligonucleotide includes the sequence TTG GGT TGG GTG GGT TGG GTT (SEQ ID NO: 3).

### Claim 12 (depends on 9)

An anti-restenosis agent according to claim 9, wherein the phosphorothioate-modified oligonucleotide includes a sequence selected from TGG GGT GGG GTG GGG TGG GGT CAG CGA AGC (SEQ ID NO: 4), and TTG GGT TGG GTG GGT TGG GTT CAG CGA AGC (SEQ ID NO: 6).

### Claim 13 (depends on 12)

An anti-restenosis agent according to claim 12, wherein the phosphorothioate-modified oligonucleotide comprises a sequence selected from TGG GGT GGG GTG GGG TGG GGT CAG CGA AGC TG (SEQ ID NO: 5) and TTG GGT TGG GTG GGT TGG GTT CAG CGA AGC TG (SEQ ID NO: 7).

### Claim 14 (depends on 1)

A device of the type which can be implanted into the body, the device having a coating comprising the anti-restenosis agent according to claim 1.

### Claim 15 (depends on 14)

A device as claimed in claim 14, which is a stent for use in percutaneous transluminal coronary angioplasty (PTCA).

### Claim 16 (depends on 14)

A device as claimed in claim 14, comprising an electrically conducting support Covered with a layer of electrically conducting polymer, in which layer is incorporated the anti-restenosis agent.

### Claim 17 (depends on 16)

A device as claimed in claim 16, in which the polymer is a polymer derived from thiophene.

### Claim 18 (depends on 17)

A device as claimed in claim 17, in which the polymer is a poly(3,4-ethylenedioxythiophene).

### Claim 19 (depends on 1)

A method of treating restenosis comprising the step of contacting affected tissue, such as smooth muscle cell tissue, with an anti-restenosis agent according to claim 1.

### Claim 20 (depends on 15, 19)

A method according to claim 19, in which a stent according to claim 15 is positioned adjacent to the affected tissue.
